Mycophenolate mofetil in the treatment of lupus nephritis

Biologics: Targets and Therapy

Volumn 2, Issue 2, 2008, Pages 297-310

  Yong, Patrick F K ^a   D'Cruz, David P ^b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

Lupus nephritis; Mycophenolate mofetil; Systemic lupus erythematosus

Indexed keywords

EID: 83255175747     PISSN: 11775475     EISSN: 11775491     Source Type: Journal    
DOI: 10.2147/btt.s2266     Document Type: Review

References (75)

1. Adams A, MacDermott EJ, Lehman TJ. 2006. Pharmacotherapy of Lupus Nephritis in Children: A Recommended Treatment Approach. Drugs, 66:1191-207.
2. Allison AC, Almquist SJ, Muller CD, et al. 1991. In vitro immunosuppressive effects of mycophenolic acid and an ester pro-drug, RS-61443. Transplant Proc, 23:10-4.
3. Allison AC, Eugui EM. 2000. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology, 47:85-118.
4. Austin HA, Illei GG. 2005. Membranous lupus nephritis. Lupus, 14:65-71.
5. Austin III HA, Klippel JH, Balow JE, et al. 1986. Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med, 314: 614-9.
6. Bastian HM, Roseman JM, McGwin G Jr et al. For the LUMINA Study Group. 2002. Systemic lupus erythematosus in three ethnic groups. XII. Risk factors for lupus nephritis after diagnosis. Lupus, 11:152-60.
7. Blaheta RA, Leckel K, Wittig B, et al. 1999. Mycophenolate mofetil impairs transendothelial migration of allogeneic CD4 and CD8 T cells. Transplant Proc, 31:1250-2.
8. Boumpas DT, Austin III HA, Vaughn EM, et al. 1992. Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet, 340:741-5.
9. Budde K, Knoll G, Curtis J. 2006. Long-term safety and efficacy after conversion of maintenance renal transplant recipients from mycophenolate mofetil (MMF) to enteric-coated mycophenolate sodium (EC-MPA, myfortic). Clin Nephrol, 66:103-11.
10. Bullingham RE, Nicholls AJ, Kamm BR. 1998. Clinical pharmacokinetics of mycophenolate mofetil. Clin Pharmacokinet, 34: 429-55.
11. Buratti S, Szer S, Spencer CH, et al. 2001. Mycophenolate mofetil treatment of severe renal disease in pediatric onset systemic lupus erythematosus. J Rheumatol, 28:2103-8.
12. Cameron JS. 1999. Lupus nephritis. J Am Soc Nephrol, 10:413-24.
13. Carr SF, Papp E, Wu JC, et al. 1993. Characterization of human type I and type II IMP dehydrogenases. J Biol Chem, 268:27286-90.
14. Chan L, Mulgaonkar S, Walker R, et al. 2006. Patient-reported gastrointestinal symptom burden and health-related quality of life following conversion from mycophenolate mofetil to enteric coated mycophenolate sodium. Transplantation, 81:1290-7.
15. Chan TM, Li FK, Tang CS, et al. 2000. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N Engl J Med, 343:1156-62.
16. Chan TM, Tse KC, Tang CS, et al. 2005. Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis. J Am Soc Nephrol, 16:1076-84.
17. Colic M, Stojic-Vukanic Z, Pavlovic B, et al. 2003. Mycophenolate mofetil inhibits differentiation, maturation and allostimulatory function of human monocyte-derived dendritic cells. Clin Exp Immunol, 134:63-9.
18. Contreras G, Pardo V, Leclercq B, et al. 2004. Sequential therapies for proliferative lupus nephritis. N Engl J Med, 350:971-80.
19. Contreras G, Tozman E, Nahar N, et al. 2005. Maintenance therapies for proliferative lupus nephritis: mycophenolate mofetil, azathioprine and intravenous cyclophosphamide. Lupus, 14(Suppl 1):S33-8.
20. Corna D, Morigi M, Facchinetti D, et al. 1997. Mycophenolate mofetil limits renal damage and prolongs life in murine lupus autoimmune disease. Kidney Int, 51:1583-9.
21. Danchenko N, Satia JA, Anthony MS. 2006. Epidemiology of systemic lupus erythematosus: a comparison of worldwide disease burden. Lupus, 15:308-18.
22. EMEA (European Medicines Agency). 2008. Cellcept, European public assessment report 2008 [online]. Accessed 1 Feburary 2008. URL: http://www.emea.europa.eu/humandocs/Humans/EPAR/cellcept/cellcept.htm
23. Flanc RS, Roberts MA, Strippoli GF, et al. 2004. Treatment of diffuse proliferative lupus nephritis: a metaanalysis of randomized controlled trials. Am J Kidney Dis, 43:197-208.
24. Flores-Suárez LF, Villa AR. 2004. Preliminary results of an open label randomised clinical trial comparing mycophenylate mofetil (MMF) vs intravenous cyclophosphamide as induction therapy for severe lupus nephritis. Arthritis Rheum, 50(Suppl):S414, 1029.
25. Fu YF, Liu GL. 2001. Mycophenolate mofetil therapy for children with lupus nephritis refractory to both intravenous cyclophosphamide and cyclosporine. Clin Nephrol, 55:318-21.
26. Furness PN, Taub N. 2006. Interobserver reproducibility and application of the ISN/RPS classification of lupus nephritis - A UK-wide study. Am J Surg Pathol, 30:1030-5.
27. Ginzler EM, Appel GB, Dooley MA, et al. 2007. Mycophenolate Mofetil and Intravenous Cyclophosphamide in the Aspreva Lupus Management Study (ALMS): Efficacy by Racial Group. Arthritis Rheum, 54(Suppl Abstract):L13.
28. Ginzler EM, Dooley MA, Aranow C, et al. 2005. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med, 353:2219-28.
29. Goldblum R. 1993. Therapy of rheumatoid arthritis with mycophenolate mofetil. Clin Exp Rheumatol, 11(Suppl 8):S117-S19.
30. Gourishankar S, McDermid JC, Jhangri GS, et al. 2004. Herpes zoster infection following solid organ transplantation: incidence, risk factors and outcomes in the current immunosuppressive era. Am J Transplant, 4:108-15.
31. Gourley MF, Austin III HA, Scott D, et al. 1996. Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial. Ann Intern Med, 125:549-57.
32. Houssiau FA, Vasconcelos C, D'Cruz D, et al. 2002. Immunosuppressive therapy in lupus nephritis. Arthritis Rheum, 46:2121-31.
33. Houssiau FA, Vasconcelos C, D'Cruz D, et al. 2004. Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial. Arthritis Rheum, 50:3934-40.
34. Jonsson CA, Svensson L, Carlsten H. 1999. Beneficial effect of the inosine monophosphate dehydrogenase inhibitor mycophenolate mofetil on survival and severity of glomerulonephritis in systemic lupus erythematosus (SLE)-prone MRLlpr/lpr mice. Clin Exp Immunol, 116:534-41.
35. Kapitsinou PP, Boletis JN, Skopouli FN, et al. 2004. Lupus nephritis: treatment with mycophenolate mofetil. Rheumatology, (Oxford) 43:377-80.
36. Karim MY, Pisoni CN, Ferro L, et al. 2005. Reduction of proteinuria with mycophenolate mofetil in predominantly membranous lupus nephropathy. Rheumatology, (Oxford) 44:1317-21.
37. Kasitanon N, Petri M, Haas M, et al. 2008. Mycophenolate mofetil as the primary treatment of membranous lupus nephritis with and without concurrent proliferative disease: a retrospective study of 29 cases. Lupus, 17:40-5.
38. Kitiyakara C, Ophascharoensuk V, Changsirikulchai S, et al. 2008. Treatment of lupus nephritis and primary glomerulonephritis with entericcoated mycophenolate sodium. Clin Nephrol, 69:90-101.
39. Lagaraine C, Lebranchu Y. 2003 Effects of immunosuppressive drugs on dendritic cells and tolerance induction. Transplantation, 75:37S-42S.
40. Lau KL, Jones DP, Hastings MC, et al. 2006. Short-term outcomes of severe lupus nephritis in a cohort of predominantly African-American children. Pediatr Nephrol, 21:655-62.
41. Le Meur Y, Büchler M, Thierry A, et al. 2007. Individualized mycophenolate mofetil dosing based on drug exposure significantly improves patient outcomes after renal transplantation. Am J Transplant, 7:2496-503.
42. Lui SL, Tsang R, Wong D et al. 2002. Effect of mycophenolate mofetil on severity of nephritis and nitric oxide production in lupus-prone MRL/lpr mice. Lupus, 11:411-8.
43. McMurray RW, Elbourne KB, Lagoo A, et al. 1998. Mycophenolate mofetil suppresses autoimmunity and mortality in the female NZB × NZW F1 mouse model of systemic lupus erythematosus. J Rheumatol, 25:2364-70.
44. Moore RA, Derry S. 2006. Systematic review and meta-analysis of randomised trials and cohort studies of mycophenolate mofetil in lupus nephritis. Art Res Ther, 8:R182.
45. Morath C, Schwenger V, Beimler J, et al. 2006. Antifibrotic actions of mycophenolic acid. Clin Transplant, 20 (Suppl 17):25-9.
46. Natsumeda Y, Ohno S, Kawasaki H, et al. 1990. Two distinct cDNAs for human IMP dehydrogenase. J Biol Chem, 265: 5292-5.
47. Nowak I, Shaw LM. 1995. Mycophenolic acid binding to human serum albumin: characterization and relation to pharmacodynamics. Clin Chem, 41:1011-7.
48. Ong LM, Hooi LS, Lim TO, et al. 2005. Randomized controlled trial of pulse intravenous cyclophosphamide versus mycophenolate mofetil in the induction therapy of proliferative lupus nephritis. Nephrology, (Carlton) 10:504-10.
49. Paredes A. 2007. Can mycophenolate mofetil substitute cyclophosphamide treatment of pediatric lupus nephritis? Pediatr Nephrol, 22:1077-82.
50. Patel M, Clarke AM, Bruce IN, et al. 2006. The prevalence and incidence of biopsy-proven lupus nephritis in the UK: Evidence of an ethnic gradient. Arthritis Rheum, 54:2963-9.
51. Pecoraro C, Malgieri G, D'Armiento M, et al. 2005. Treatment of childhood lupus nephritis with mycophenolate mofetil: clinical and histopathological study. J Am Soc Nephrol, 16:557A.
52. Perez-Aytes A, Ledo A, Boso V, et al. 2008. In utero exposure to mycophenolate mofetil: a characteristic phenotype? Am J Med Genet, 146:1-7.
53. Ramos MA, Pinera C, Setien MA, et al. 2003. Modulation of autoantibody production by mycophenolate mofetil: effects on (NZB × NZW) F1 mice. Nephrol Dial Transplant, 18:878-83.
54. Roos N, Poulalhon N, Farge D, et al. 2007. In vitro evidence for a direct antifibrotic role of the immunosuppressive drug mycophenolate mofetil. J Pharmacol Exp Ther, 321:583-9.
55. Salvadori M, Holzer H, de Mattos A, et al. 2004. Enteric-coated mycophenolate sodium is therapeutically equivalent to mycophenolate mofetil in de novo renal transplant patients. Am J Transplant, 4:231-6.
56. Senda M, DeLustro B, Eugui E, et al. 1995. Mycophenolic acid, an inhibitor of IMP dehydrogenase that is also an immunosuppressive agent, suppresses the cytokine-induced nitric oxide production in mouse and rat vascular endothelial cells. Transplantation, 60:1143-8.
57. Sinclair A, Appel G, Dooley MA, et al. 2007. Mycophenolate mofetil as induction and maintenance therapy for lupus nephritis: rationale and protocol for the randomized, controlled Aspreva Lupus Management Study (ALMS). Lupus, 16:972-80.
58. Song AT, Abdala E, Bonazzi PR, et al. 2006. Does mycophenolate mofetil increase the risk of cytomegalovirus infection in solid organ transplant recipients?A mini-review. Braz J Infect Dis, 10:132-8.
59. Spetie DN, Tang Y, Rovin BH, et al. 2004. Mycophenolate therapy of SLE membranous nephropathy. Kidney Int, 66:2411-5.
60. Trager J, Ward MM. 2001. Mortality and causes of death in systemic lupus erythematosus. Curr Opin Rheumatol, 13:345-51.
61. Tse KC, Tang CSO, Lio WI, et al. 2006. Quality of life comparison between corticosteroid-and-mycofenolate mofetil and corticosteroid-and-oral cyclophosphamide in the treatment of severe lupus nephritis. Lupus, 15:371-9.
62. Van Bruggen MC, Walgreen B, Rijke TP, et al. 1998. Attenuation of murine lupus nephritis by mycophenolate mofetil. J Am Soc Nephrol, 9:1407-15.
63. van Gelder T, Hilbrands LB, Vanrenterghem Y, et al. 1999. A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation. Transplantation, 68:261-6.
64. van Gelder T, Shaw LM. 2005. The rationale for and limitations of therapeutic drug monitoring for mycophenolate mofetil in transplantation. Transplantation, 80(2 Suppl):S244-53.
65. van Hest RM, Mathot RA, Pescovitz MD, et al. 2006. Explaining variability in mycophenolic acid exposure to optimize mycophenolate mofetil dosing: a population pharmacokinetic meta-analysis of mycophenolic acid in renal transplant recipients. J Am Soc Nephrol, 17:871-80.
66. Walsh M, James M, Jayne D, et al. 2007. Mycophenolate mofetil for induction therapy of lupus nephritis: a systematic review and metaanalysis. Clin J Am Soc Nephrol, 2:968-75.
67. Wang K, Zhang H, Li Y, et al. 2004. Safety of mycophenolate mofetil versus azathioprine in renal transplantation: a systematic review. Transplant Proc, 36:2068-70.
68. Weber LT, Shipkova M, Armstrong VW, et al. 2002. The pharmacokinetic-pharmacodynamic relationship for total and free mycophenolic acid in pediatric renal transplant recipients: A report of the German Study Group on Mycophenolate Mofetil Therapy. J Am Soc Nephrol, 13:759-68.
69. Weening JJ, D'Agati VD, Schwartz MM, et al. 2004. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol, 15:241-50.
70. Wilson ECF, Jayne DRW, Dellow E, et al. 2007. The cost-effectiveness of mycophenolate mofetil as firstline therapy in active lupus nephritis. Rheumatology, 46:1096-101.
71. Ye Z, Tan YH, Hong XP, et al. 2001. MMF vs CTX in the treatment of severe SLE patients. Lupus, 10(Suppl 1):S99-S274.
72. Yokoyama H, Wada T, Hara A, et al. 2004. The outcome and a new ISN/RPS 2003 classification of lupus nephritis in Japanese. Kidney Int, 66:2382-8.
73. Yu CC, Yang CW, Wu MS, et al. 2001. Mycophenolate mofetil reduces renal cortical inducible nitric oxide synthase mRNA expression and diminishes glomerulosclerosis in MRL/lpr mice. J Lab Clin Med, 138:69-77.
74. Zhu B, Chen N, Lin Y, et al. 2007. Mycophenolate mofetil in induction therapy of severe lupus nephritis: a meta-analysis of randomized controlled trials. Nephrol Dial Transplant, 22:1933-42.
75. Zoja C, Benigni A, Noris M, et al. 2001. Mycophenolate mofetil combined with a cyclooxygenase-2 inhibitor ameliorates murine lupus nephritis. Kidney Int, 60:653-63.